The United States Bone Morphogenetic Proteins 7 market size was valued at USD 98.6 million in 2024 and is projected to reach USD 134.7 million by 2030, at a CAGR of 5.3% during the forecast period 2024-2030.
Bone Morphogenetic Protein 7 (BMP-7) is a growth factor that stimulates bone and cartilage formation, used in orthopedic and dental procedures to enhance bone healing and regeneration.
The U.S. Bone Morphogenetic Proteins 7 market is experiencing moderate growth, driven by an aging population and increasing orthopedic surgeries. In 2023, total consumption reached 25,000 units, with spinal fusion procedures accounting for 50% of demand. The dental implant segment is growing at 7% annually. The market saw a 12% increase in demand for BMP-7 in non‑union fracture treatments in 2023. Combination therapies using BMP‑7 with other growth factors are growing at 9% annually, driven by improved efficacy. The trend towards minimally invasive surgeries led to a 15% rise in adoption of injectable BMP‑7 formulations. Off‑label use in cosmetic and reconstructive surgeries saw a 10% surge, despite regulatory challenges. The market is witnessing increased focus on developing sustained‑release formulations, with a 20% growth in R&D investments for improved delivery systems.
This report contains market size and forecasts of Bone Morphogenetic Proteins 7 in United States, including the following market information:
- United States Bone Morphogenetic Proteins 7 Market Revenue, 2019-2024, 2024-2030, ($ millions)
- United States Bone Morphogenetic Proteins 7 Market Sales, 2019-2024, 2024-2030
- United States Top five Bone Morphogenetic Proteins 7 companies in 2023 (%)
Report Includes
This report presents an overview of United States market for Bone Morphogenetic Proteins 7, sales, revenue and price. Analyses of the United States market trends, with historic market revenue/sales data for 2019-2023, estimates for 2024, and projections of CAGR through 2030.
This report focuses on the Bone Morphogenetic Proteins 7 sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the United States Bone Morphogenetic Proteins 7 market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues.
This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
For a deeper dive,
United States Bone Morphogenetic Proteins 7 Market – View in Detailed Research Report
Top 10 Companies in the United States Bone Morphogenetic Proteins 7 Market (2026)
1️⃣ Medtronic
Headquarters: Minneapolis, Minnesota, USA
Key Offering: BMP‑7 Bone Graft Products, Spinal Fusion Kits
Medtronic has been a pioneer in spinal fusion technology, integrating BMP‑7 into its advanced bone graft substitutes. The company’s BMP‑7 formulations are known for rapid osteogenesis and reduced fusion time.
Sustainability & Growth Initiatives:
- Investment in biodegradable carriers for BMP‑7
- Partnerships with orthopedic surgeons to expand minimally invasive BMP‑7 delivery
- R&D focus on dual‑growth factor combinations
2️⃣ Stryker Corporation
Headquarters: Kalamazoo, Michigan, USA
Key Offering: BMP‑7 Enhanced Bone Grafts, Orthopedic Implants
Stryker’s BMP‑7 products are integrated into its modular spine and joint replacement systems, offering surgeons a reliable bone-healing option.
Sustainability & Growth Initiatives:
- Development of sustained‑release BMP‑7 delivery platforms
- Clinical trials in trauma and reconstructive applications
- Eco‑friendly manufacturing processes for BMP‑7 carriers
3️⃣ Zimmer Biomet
Headquarters: Warsaw, Indiana, USA
Key Offering: BMP‑7 Bone Graft Products, Spinal Fusion Devices
Zimmer Biomet’s BMP‑7 line is widely used in spinal fusion and orthopedic trauma, supporting rapid bone healing with high success rates.
Sustainability & Growth Initiatives:
- Expansion of BMP‑7 in dental implant applications
- Collaborations with research institutions for novel delivery systems
- Reduction of carbon footprint in BMP‑7 production
4️⃣ DePuy Synthes (Johnson & Johnson)
Headquarters: Memphis, Tennessee, USA
Key Offering: BMP‑7 Bone Graft Substitutes, Trauma Solutions
DePuy Synthes incorporates BMP‑7 into its trauma and orthopedic product lines, enhancing bone regeneration in complex fractures.
Sustainability & Growth Initiatives:
- Investments in advanced biomaterial carriers for BMP‑7
- Clinical studies focusing on non‑union fracture treatment
- Partnerships for sustainable sourcing of BMP‑7 components
5️⃣ Thermo Fisher Scientific
Headquarters: Waltham, Massachusetts, USA
Key Offering: BMP‑7 Protein Production, Research Reagents
Thermo Fisher supplies high‑purity BMP‑7 protein for research and clinical use, supporting innovation in bone healing technologies.
Sustainability & Growth Initiatives:
- Scale-up of GMP‑grade BMP‑7 manufacturing
- Research into recombinant BMP‑7 production efficiencies
- Environmental stewardship in laboratory operations
6️⃣ BioHorizons
Headquarters: Irvine, California, USA
Key Offering: BMP‑7 Bone Graft Products, Spinal Fusion Kits
BioHorizons focuses on BMP‑7 based bone grafts that provide robust osteoconduction and osteoinduction for spinal and trauma applications.
Sustainability & Growth Initiatives:
- Development of injectable BMP‑7 formulations
- Clinical trials in dental implant and reconstructive surgery
- Adoption of green chemistry in BMP‑7 synthesis
7️⃣ Orthofix Medical Inc.
Headquarters: Lake Forest, California, USA
Key Offering: BMP‑7 Enhanced Bone Grafts, Orthopedic Devices
Orthofix integrates BMP‑7 into its spinal and orthopedic device portfolio, emphasizing minimally invasive delivery and patient‑centric outcomes.
Sustainability & Growth Initiatives:
- Investments in sustained‑release BMP‑7 carriers
- Partnerships with surgical societies for BMP‑7 adoption
- Efforts to reduce waste in BMP‑7 device manufacturing
8️⃣ NuVasive, Inc.
Headquarters: Pleasanton, California, USA
Key Offering: BMP‑7 Bone Graft Products, Spine Surgery Solutions
NuVasive’s BMP‑7 products are tailored for spinal fusion and trauma, offering high osteogenic potential with a focus on minimally invasive techniques.
Sustainability & Growth Initiatives:
- Research on BMP‑7 delivery via hydrogel systems
- Clinical trials in non‑union fracture management
- Commitment to sustainable supply chain practices
9️⃣ Wright Medical Group N.V.
Headquarters: New York, New York, USA
Key Offering: BMP‑7 Bone Graft Products, Orthopedic Implants
Wright Medical’s BMP‑7 line supports a range of orthopedic procedures, with an emphasis on rapid bone healing and reduced surgical time.
Sustainability & Growth Initiatives:
- Development of biodegradable BMP‑7 carriers
- Partnerships for expanded BMP‑7 indications
- Investment in green manufacturing technologies
🔟 Smith & Nephew
Headquarters: London, United Kingdom (U.S. operations in New Jersey, USA)
Key Offering: BMP‑7 Bone Graft Products, Trauma and Spinal Devices
Smith & Nephew’s BMP‑7 products are used in complex fracture fixation and spinal fusion, delivering reliable bone regeneration across diverse patient populations.
Sustainability & Growth Initiatives:
- Investments in sustained‑release BMP‑7 formulations
- Clinical studies in dental and reconstructive applications
- Commitment to reducing environmental impact of BMP‑7 manufacturing
Download FREE Sample Report: United States Bone Morphogenetic Proteins 7 Market – Sample Report
Get Full Report: United States Bone Morphogenetic Proteins 7 Market – Full Report
🌍 Outlook: The Future of Bone Morphogenetic Proteins 7 Market in the United States
The BMP‑7 market is poised for steady expansion, driven by demographic shifts, surgical innovation, and the push for minimally invasive therapies. Forecasts indicate that the market will continue to grow at a CAGR of 5.3% from 2025 to 2034, reaching a value of USD 134.7 million by 2030 and beyond.
📈 Key Trends Shaping the Market:
- Adoption of injectable BMP‑7 formulations in spinal fusion and trauma surgeries.
- Growth of combination therapies pairing BMP‑7 with other growth factors.
- Increased investment in sustained‑release delivery systems.
- Expansion of BMP‑7 applications in dental implants and reconstructive procedures.
- Regulatory focus on off‑label uses and safety profiling.
Companies that invest in innovative delivery platforms and broaden BMP‑7 indications are likely to capture the fastest-growing segments.
🔮 Future Trends: Emerging Opportunities and Challenges
• Bioprinting and Tissue Engineering: Integration of BMP‑7 into 3D‑printed bone scaffolds could revolutionize complex reconstruction.
• Digital Health Integration: Smart delivery devices that monitor BMP‑7 release and bone healing will enhance patient outcomes.
• Regulatory Landscape: Stricter oversight of off‑label uses may constrain growth but also drive higher quality standards.
• Competitive Dynamics: Consolidation among BMP‑7 suppliers and strategic alliances with orthopedic device manufacturers will shape market leadership.
- Top 10 Companies in the Latin America Cera Flava (Yellow Wax) Market (2026): Market Leaders Powering Regional Growth - June 18, 2026
- Top 10 Companies in the Tetrabromophthalate Diol (PHT4-Diol) Market (2026): Market Leaders Driving Global Flame Retardant Innovation - June 18, 2026
- Top 10 Companies in the Global Sintered Steel Market (2026): Market Leaders Powering Global Industry - June 18, 2026